sorafenib has been researched along with Cancer of Pancreas in 57 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (12.28) | 29.6817 |
| 2010's | 45 (78.95) | 24.3611 |
| 2020's | 5 (8.77) | 2.80 |
| Authors | Studies |
|---|---|
| Peedell, C; Polwart, C; Wadd, N | 1 |
| Aisner, J; Cerchio, R; Chan, N; Chen, S; Ganesan, S; Goodin, S; Gounder, M; Li, J; Lin, H; Malhotra, J; Marinaro, C; Mehnert, JM; Portal, DE; Shih, W; Silk, AW; Spencer, KR; Stein, MN | 1 |
| Chen, J; Chen, Y; Li, P; Wang, S | 1 |
| Booth, L; Dent, P; Poklepovic, A | 1 |
| Bahra, M; Bechstein, W; Bischoff, S; Bitzer, M; Denzlinger, C; Gellert, K; Ghadimi, M; Hinke, A; Hofheinz, R; Lammert, F; Liersch, T; Lindig, U; Maschmeyer, G; Oettle, H; Pelzer, U; Riess, H; Sinn, M; Striefler, JK; Stübs, P; Waldschmidt, D | 1 |
| He, J; Jia, B; Yan, J; Yang, J | 1 |
| Coleman, EL; Cowper, SE; Leventhal, JS; Stein, SM | 1 |
| Fang, Z; Han, B; Hong, SS; Jung, KH; Kang, YW; Kim, SJ; Lee, JE; Lim, JH; Park, JH; Rumman, M; Yan, HH | 1 |
| Booth, L; Dent, P; Poklepovic, A; Roberts, JL | 1 |
| Kutkowska, J; Rapak, A; Strzadala, L | 1 |
| Fetterly, GJ; Hylander, BH; Jusko, WJ; Ma, WW; Pawaskar, DK; Repasky, EA; Straubinger, RM | 2 |
| Awasthi, N; Hinz, S; Schwarz, MA; Schwarz, RE; Zhang, C | 1 |
| Aitini, E; Barni, S; Berardi, R; Bidoli, P; Boni, C; Caprioni, F; Cascinu, S; Cinquini, M; Conte, P; Di Costanzo, F; Faloppi, L; Ferrari, D; Labianca, R; Mosconi, S; Siena, S; Sobrero, A; Tonini, G; Villa, F; Zagonel, V | 1 |
| Saif, MW | 1 |
| Baudin, E; Borson-Chazot, F; Hescot, S; Lombès, M | 1 |
| Aparicio, J; Ayuso, JR; Conill, C; Feliu, J; Fuster, D; García-Mora, C; Martín, M; Maurel, J; Petriz, ML; Sánchez-Santos, ME | 1 |
| Berlin, J; Cardin, DB; Chan, E; DeVore, R; Goff, L; Grigorieva, J; Holloway, M; Li, CI; McClanahan, P; Meyer, K; Schlabach, L; Shyr, Y; Winkler, C | 1 |
| Akisik, FM; Anderson, S; Bu, G; Cardenes, HR; Chiorean, EG; Clark, R; Deluca, J; DeWitt, J; Helft, P; Johnson, CS; Johnston, EL; Loehrer, PJ; Perkins, SM; Sandrasegaran, K; Schneider, BP; Shahda, S; Spittler, AJ | 1 |
| Atkinson, B; Eatock, M; Graham, U | 1 |
| Chen, X; Feng, Z; Li, C; Li, Y; Niu, F; Tang, K; Yang, H; Zhang, L; Zhou, W | 1 |
| Eickhoff, J; Groteluschen, D; LoConte, NK; Lubner, SJ; Makielski, RJ; Mulkerin, DL; Traynor, AM | 1 |
| Aitini, E; Andrikou, K; Barni, S; Berardi, R; Bianconi, M; Bittoni, A; Boni, C; Caprioni, F; Cascinu, S; Cinquini, M; Faloppi, L; Fanello, S; Ferrari, D; Giampieri, R; Labianca, R; Mosconi, S; Scartozzi, M; Sobrero, A; Torri, V; Zaniboni, A | 1 |
| Hammock, BD; Hwang, SH; Li, H; Liao, J; Liu, JY; Wecksler, AT; Yang, GY; Yang, J; Yang, Y | 1 |
| Amadori, D; Arienti, C; Carloni, S; Fabbri, F; Silvestrini, R; Tesei, A; Ulivi, P; Vannini, I; Zoli, W | 1 |
| Wang, ZY | 1 |
| Huang, S; Sinicrope, FA | 1 |
| Carr, BI; Wang, M; Wei, G | 1 |
| Greten, TF; Manns, MP; Plentz, RR | 1 |
| Beljanski, V; Knaak, C; Smith, CD; Zhuang, Y | 1 |
| Amadori, D; Arienti, C; Carloni, S; Chiadini, E; Fabbri, F; Leonetti, C; Milandri, C; Orlandi, A; Passeri, D; Scarsella, M; Silvestrini, R; Tesei, A; Ulivi, P; Zoli, W; Zupi, G | 1 |
| Akisik, MF; Bu, G; Chiorean, EG; Hutchins, GD; Lin, C; Sandrasegaran, K | 1 |
| Baumann, B; Büchler, MW; Gladkich, J; Herr, I; Kallifatidis, G; Liu, L; Mattern, J; Rausch, V; Salnikov, AV; Schemmer, P; Wirth, T; Zöller, M | 1 |
| Beck, J; Bellmunt, J; Escudier, B | 1 |
| Crea, F; Danesi, R; Del Tacca, M; Mey, V; Nannizzi, S; Pasqualetti, G; Ricciardi, S | 1 |
| Agamah, E; Hall, MJ; Kindler, HL; Locker, G; Nattam, S; Stadler, WM; Vokes, EE; Wallace, JA; Wroblewski, K | 1 |
| Azzariti, A; Colucci, G; Fratto, ME; Galluzzo, S; Maiello, E; Santini, D; Silvestris, N; Tommasi, S; Tonini, G; Vincenzi, B; Zoccoli, A | 1 |
| Barbara, C; Barni, S; Cabiddu, M; Colombo, S; Corti, D; Elia, S; Ghilardi, M; Petrelli, F; Stringhi, E | 1 |
| Oberstein, PE; Saif, MW | 1 |
| El-Khoueiry, AB; Gandara, D; Lenz, HJ; Ramanathan, RK; Shibata, S; Wright, JJ; Yang, DY; Zhang, W | 1 |
| Allen, E; Hanahan, D; Walters, IB | 1 |
| Hong, SH; Jeon, EK; Jeong, HK; Ko, YH; Lee, SL; Roh, SY; Shin, OR; Won, HS | 1 |
| Chen, R; Curley, SA; Liu, H; McConkey, DJ; Ward, JF; Zhang, T | 1 |
| Bellail, AC; Ding, L; Hao, C; Liu, Y; Lu, G; Olson, JJ; Sun, SY; Wang, G; Wei, F; Yuan, C | 1 |
| Liu, BX; Ying, JE; Zhu, LM | 1 |
| Abalkhail, H; Al Sohaibani, F; Almanea, H; AlQaraawi, A; Alzahrani, AS | 1 |
| Dahan, L; Delpero, JR; Esterni, B; François, E; Gasmi, M; Genre, D; Gilabert, M; Giovannini, M; Gonçalves, A; Lamy, R; Largillier, R; Moureau-Zabotto, L; Perrier, H; Raoul, JL; Re, D; Seitz, JF; Tchiknavorian, X; Turrini, O; Viens, P | 1 |
| Halfdanarson, TR; Naraev, BG; Strosberg, JR | 1 |
| Fetterly, GJ; Jusko, WJ; Ma, WW; Pawaskar, DK; Straubinger, RM | 1 |
| Deming, DA; Goggins, T; Groteluschen, D; Hernan, HR; Holen, KD; LoConte, NK; Lubner, SJ; Mulkerin, DL; Oettel, K; Robinson, E; Schelman, WR; Traynor, AM | 1 |
| Hong, S; Hong, SS; Jung, KH; Lee, H; Park, BH; Seo, JH; Son, MK; Yan, HH; Yun, SM | 1 |
| Bartsch, DK; Buchholz, M; Fendrich, V; Holler, JP; Maschuw, K; Rehm, J; Slater, EP; Waldmann, J | 1 |
| Awada, A; Giannaris, T; Lathia, C; Moore, MJ; Petrenciuc, O; Piccart, M; Schwartz, B; Siu, LL; Takimoto, CH | 1 |
| Von Hoff, DD | 1 |
| Hobday, TJ; McWilliams, RR; Morris, JC; Robinson, SI; Sathananthan, A | 1 |
| Di Fiore, F; Michel, P | 1 |
| Burris, H; Rocha-Lima, C | 1 |
9 review(s) available for sorafenib and Cancer of Pancreas
| Article | Year |
|---|---|
[Targeted therapies, prognostic and predictive factors in endocrine oncology].
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials, Phase III as Topic; Disease-Free Survival; Endocrine Gland Neoplasms; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperidines; Prognosis; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Outcome | 2013 |
[Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Deoxycytidine; Drug Delivery Systems; Gastrointestinal Stromal Tumors; Gemcitabine; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2009 |
Molecular therapy of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Neoplasm Invasiveness; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phthalazines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
In vitro and in vivo antitumor efficacy of docetaxel and sorafenib combination in human pancreatic cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Docetaxel; Drug Interactions; Humans; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Taxoids | 2010 |
Targeting EGFR in bilio-pancreatic and liver carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Biliary Tract Neoplasms; Carcinoma; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Liver Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib | 2011 |
Developments in metastatic pancreatic cancer: is gemcitabine still the standard?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Humans; Meta-Analysis as Topic; Neoplasm Metastasis; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib | 2012 |
Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Differentiation; ErbB Receptors; Everolimus; Histone Deacetylases; Humans; Immunologic Factors; Indazoles; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptors, Somatostatin; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2012 |
What's new in pancreatic cancer treatment pipeline?
Topics: Adenoviridae; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Cancer Vaccines; Cetuximab; Cyclic N-Oxides; Deoxycytidine; Drug Combinations; Gastrins; Gemcitabine; Humans; Niacinamide; Oxonic Acid; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Sulfonamides; Tegafur; Tumor Necrosis Factor-alpha | 2006 |
New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Benzenesulfonates; Bevacizumab; Cetuximab; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib | 2008 |
15 trial(s) available for sorafenib and Cancer of Pancreas
| Article | Year |
|---|---|
A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Maximum Tolerated Dose; Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Riluzole; Sorafenib | 2023 |
Neratinib decreases pro-survival responses of [sorafenib + vorinostat] in pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Line, Tumor; Cell Survival; Female; Humans; Male; Mice; Mice, Nude; Pancreatic Neoplasms; Quinolines; Sorafenib; Vorinostat | 2020 |
CONKO-006: A randomised double-blinded phase IIb-study of additive therapy with gemcitabine + sorafenib/placebo in patients with R1 resection of pancreatic cancer - Final results.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Double-Blind Method; Drug Administration Schedule; Female; Gemcitabine; Germany; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pancreatectomy; Pancreatic Neoplasms; Sorafenib; Time Factors; Treatment Outcome | 2020 |
Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Positron-Emission Tomography; Sorafenib; Tomography, X-Ray Computed | 2014 |
Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Quinazolines; Sorafenib | 2014 |
Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Gemcitabine; Genotype; Humans; Induction Chemotherapy; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Polymorphism, Single Nucleotide; Prospective Studies; Radiotherapy, Intensity-Modulated; Sorafenib; Tumor Burden; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Niacinamide; Organoplatinum Compounds; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib | 2015 |
The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Prognosis; Sorafenib | 2015 |
Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Contrast Media; Female; Gadolinium DTPA; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Prognosis; Pyridines; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome | 2010 |
Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Chicago; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Time Factors; Treatment Outcome; Universities | 2012 |
A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cyclooxygenase 2; Cytidine Deaminase; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Nucleoside Deaminases; Pancreatic Neoplasms; Phenylurea Compounds; Polymorphism, Single Nucleotide; Pyridines; Ribonucleoside Diphosphate Reductase; Sorafenib; Tumor Suppressor Proteins | 2012 |
BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Placebos; Protein Kinase Inhibitors; Ribonucleotide Reductases; Sorafenib | 2012 |
A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Demography; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Phenylurea Compounds; Sorafenib; Treatment Outcome; Wisconsin | 2013 |
Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib | 2006 |
33 other study(ies) available for sorafenib and Cancer of Pancreas
| Article | Year |
|---|---|
Real-World Assessment of Cancer Drugs Using Local Data Uploaded to the Systemic Anti-Cancer Therapy Dataset in England.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Paclitaxel; Pancreatic Neoplasms; Sorafenib; State Medicine; Trifluridine | 2022 |
LINC01133 can induce acquired ferroptosis resistance by enhancing the FSP1 mRNA stability through forming the LINC01133-FUS-FSP1 complex.
Topics: Cell Line, Tumor; Ferroptosis; Humans; Pancreatic Neoplasms; RNA Stability; RNA-Binding Protein FUS; RNA, Long Noncoding; Sorafenib | 2023 |
Glycaemic adverse drug reactions from anti-neoplastics used in treating pancreatic cancer.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Blood Glucose; China; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Hyperglycemia; Incidence; Male; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Registries; Sorafenib | 2017 |
Erythema Nodosum-like Eruption in the Setting of Sorafenib Therapy.
Topics: Adenomatous Polyposis Coli; Aged; Antineoplastic Agents; Duodenal Neoplasms; Erythema Nodosum; Female; Fibroma; Humans; Middle Aged; Neoplasms, Multiple Primary; Pancreatic Neoplasms; Sorafenib | 2018 |
Melatonin Synergizes with Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR-β/STAT3 Pathway.
Topics: Cell Line, Tumor; Drug Synergism; Humans; Melatonin; Neoplasm Proteins; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Receptor, Platelet-Derived Growth Factor alpha; Receptors, Melatonin; Signal Transduction; Sorafenib; STAT3 Transcription Factor | 2018 |
Prior exposure of pancreatic tumors to [sorafenib + vorinostat] enhances the efficacy of an anti-PD-1 antibody.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disease Models, Animal; Drug Screening Assays, Antitumor; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Male; Mice; Pancreatic Neoplasms; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Sorafenib; Vorinostat | 2019 |
Sorafenib in Combination with Betulinic Acid Synergistically Induces Cell Cycle Arrest and Inhibits Clonogenic Activity in Pancreatic Ductal Adenocarcinoma Cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Betulinic Acid; Cell Cycle Checkpoints; Cell Line, Tumor; Drug Synergism; Humans; Pancreatic Neoplasms; Pentacyclic Triterpenes; Sorafenib; Triterpenes; Tumor Stem Cell Assay | 2018 |
Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chromatography, Liquid; Drug Interactions; Everolimus; Male; Mice; Mice, Inbred BALB C; Mice, SCID; Models, Biological; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Sirolimus; Sorafenib; Tandem Mass Spectrometry; Tissue Distribution | 2013 |
Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice.
Topics: Animals; Antineoplastic Agents; Disease Progression; Dose-Response Relationship, Drug; Drug Synergism; Everolimus; Humans; Mice; Mice, SCID; Models, Biological; Molecular Targeted Therapy; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Cytokines; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, SCID; Neoplasm Proteins; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Prognosis; Random Allocation; RNA-Binding Proteins; Sorafenib; Survival Analysis; Xenograft Model Antitumor Assays | 2013 |
Pancreatic cancer: Sorafenib: no effect on efficacy of chemotherapy in pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Neovascularization, Pathologic; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
Use of sorafenib in a corticotropin-secreting pancreatic neuroendocrine carcinoma.
Topics: Adrenocorticotropic Hormone; Antineoplastic Agents; Carcinoma, Neuroendocrine; Humans; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
The molecular mechanisms of a novel multi-kinase inhibitor ZLJ33 in suppressing pancreatic cancer growth.
Topics: Animals; beta Catenin; Blotting, Western; Cell Movement; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Hydrazines; Immunoprecipitation; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Proliferating Cell Nuclear Antigen; Protein Kinase Inhibitors; Sorafenib; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2015 |
Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzoates; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Epoxide Hydrolases; Extracellular Signal-Regulated MAP Kinases; Genes, ras; Genetic Predisposition to Disease; Male; Mice, Inbred C57BL; Mice, Mutant Strains; Mutation; Niacinamide; Oxylipins; Pancreatic Neoplasms; Phenotype; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Signal Transduction; Sorafenib; Tumor Burden; Urea | 2016 |
Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Genes, ras; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyridines; raf Kinases; RNA Interference; RNA, Messenger; RNA, Small Interfering; Sorafenib; STAT3 Transcription Factor; Time Factors | 2009 |
Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Benzenesulfonates; Carcinoma; Drug Evaluation, Preclinical; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Pyridines; RNA, Small Interfering; Sorafenib; STAT3 Transcription Factor; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured | 2010 |
Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; BH3 Interacting Domain Death Agonist Protein; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Fas Ligand Protein; Fas-Associated Death Domain Protein; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-jun; Pyridines; raf Kinases; Sorafenib; Vitamin K 1 | 2010 |
Combined anticancer effects of sphingosine kinase inhibitors and sorafenib.
Topics: Adamantane; Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Caspase 3; Caspase 7; Catechols; Cell Line, Tumor; DNA Fragmentation; Drug Synergism; Female; Humans; Kidney Neoplasms; Mice; Mice, SCID; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phosphotransferases (Alcohol Group Acceptor); Pyridines; Sorafenib; Xenograft Model Antitumor Assays | 2011 |
Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Proliferation; Cells, Cultured; Colony-Forming Units Assay; Drug Synergism; Electrophoretic Mobility Shift Assay; Female; Fibroblasts; Humans; Immunoblotting; Immunoenzyme Techniques; Isoenzymes; Isothiocyanates; Luciferases; Mice; Mice, Nude; Neoplastic Stem Cells; Neovascularization, Pathologic; NF-kappa B; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Retinal Dehydrogenase; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Skin; Sorafenib; Spheroids, Cellular; Sulfoxides; Thiocyanates; Xenograft Model Antitumor Assays | 2010 |
Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Everolimus; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib | 2011 |
Synergistic cytotoxicity and molecular interaction on drug targets of sorafenib and gemcitabine in human pancreas cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; MAP Kinase Kinase Kinases; Mitogen-Activated Protein Kinase Kinases; Molecular Targeted Therapy; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phosphatidylinositol 3-Kinase; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; Sorafenib | 2010 |
A rare case of metastatic pancreatic hepatoid carcinoma treated with sorafenib.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Humans; Male; Neoplasm Metastasis; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed | 2012 |
First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Lapatinib; Medicine, Chinese Traditional; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Treatment Outcome | 2011 |
Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition.
Topics: Alanine; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Blotting, Western; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Mice; Mice, Knockout; Mice, Transgenic; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Fibroblast Growth Factor; Sorafenib; Treatment Outcome; Triazines; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Pancreatic endocrine tumors: a report on a patient treated with sorafenib.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Humans; Liver Neoplasms; Male; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Salvage Therapy; Skin Diseases; Sorafenib; Tomography, X-Ray Computed | 2011 |
Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG.
Topics: Antineoplastic Agents; Benzenesulfonates; Benzoquinones; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Mutation; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; RNA, Small Interfering; Signal Transduction; Sorafenib; Tumor Suppressor Protein p53 | 2012 |
K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Everolimus; Extracellular Signal-Regulated MAP Kinases; Feedback, Physiological; Female; Humans; Insulin-Like Growth Factor I; MAP Kinase Signaling System; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Mutation; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; Pyrimidines; Pyrroles; ras Proteins; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2012 |
Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy.
Topics: Benzenesulfonates; Biopsy; Carcinoma; Carcinoma, Papillary; Disease Progression; Endoscopy; Fatal Outcome; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Positron-Emission Tomography; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Tomography, X-Ray Computed; Ultrasonography | 2012 |
Interactions of everolimus and sorafenib in pancreatic cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Interactions; Everolimus; Humans; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Sirolimus; Sorafenib | 2013 |
Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Drug Synergism; Enzyme Inhibitors; Fluorescent Antibody Technique; Humans; In Situ Nick-End Labeling; Male; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Pyridines; Sorafenib; Sulfonamides | 2013 |
Sorafenib inhibits tumor growth and improves survival in a transgenic mouse model of pancreatic islet cell tumors.
Topics: Adenoma, Islet Cell; Animals; Antigens, Polyomavirus Transforming; Apoptosis; Disease Progression; Female; Insulin; Islets of Langerhans; Kaplan-Meier Estimate; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neovascularization, Pathologic; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Promoter Regions, Genetic; Protein Kinase Inhibitors; Rats; Sorafenib; Time Factors; Treatment Outcome; Tumor Burden | 2012 |
Can sorafenib cause hypothyroidism?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Islet Cell; Female; Humans; Hypothyroidism; Liver Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib | 2007 |
[News in digestive oncology].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cardia; Colonic Neoplasms; Combined Modality Therapy; Digestive System Neoplasms; Esophageal Neoplasms; Humans; Liver Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Stomach Neoplasms | 2008 |